Drugs / XG004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05454020 | Jun 2022 → Jan 2023 | — | Xgene Pharmaceutical Group | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XG004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05454020 ↗ |
| Route | Topical | “XG004 gel in two concentrations (5% and 10%) will be applied topically” NCT05454020 ↗ |